Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.32 |
| ▸ | THRA | P10827 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18193760 | 0.87 | ESR1 (0.35) | ESR1ESR2MAOBFFAR4THRA | |
| SCHEMBL20202938 | 0.87 | ESR1 (0.38) | ESR1ESR2MAOBKDM1AFFAR4 | |
| SCHEMBL16210206 | 0.85 | FFAR4 (0.38) | ESR1ESR2MAOBFFAR4MCL1 | |
| SCHEMBL16626973 | 0.84 | MAOA (0.37) | ESR1ESR2MAOBFFAR4F10 | |
| SCHEMBL20202939 | 0.83 | FFAR4 (0.37) | ESR1ESR2FFAR4 | |
| SCHEMBL20202929 | 0.82 | RARB (0.41) | ESR1FFAR4MAPT | |
| SCHEMBL20202936 | 0.80 | FFAR4 (0.35) | ESR1ESR2MAOBKDM1AFFAR4 | |
| SCHEMBL20202962 | 0.80 | FFAR4 (0.35) | ESR1ESR2MAOBKDM1AFFAR4 | |
| SCHEMBL15088625 | 0.78 | RXRA (0.43) | MAOBF10F9MAOA | |
| SCHEMBL16210464 | 0.78 | FFAR4 (0.36) | ESR1ESR2FFAR4F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573923-B2 | Liquid crystal compound having 2, 6-difluorophenylether structure, and liquid crystal composition containing the same | DIC CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9573923-B2 | Liquid crystal compound having 2, 6-difluorophenylether structure, and liquid crystal composition containing the same | DIC CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160159765-A1 | LIQUID CRYSTAL COMPOUND HAVING 2, 6-DIFLUOROPHENYLETHER STRUCTURE, AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME | DIC CORPORATION (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159765-A1 | LIQUID CRYSTAL COMPOUND HAVING 2, 6-DIFLUOROPHENYLETHER STRUCTURE, AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME | DIC CORPORATION (JP) | 2016-06-09 | — | — | US | disclosed |
| WO-2015049940-A1 | LIQUID CRYSTALLINE COMPOUND HAVING 2,6-DIFLUOROPHENYL ETHER STRUCTURE AND LIQUID CRYSTAL COMPOSITION CONTAINING SAME | DIC株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159765-A1 | LIQUID CRYSTAL COMPOUND HAVING 2, 6-DIFLUOROPHENYLETHER STRUCTURE, AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME | FGFR2, FGFR1, FGF2 | ESR1 3184/4885ESR2 3816/4885MAOB 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.